Loading…
Creative Medical Technology Holdings, Inc. is projected to rise to $0.8023 by 2027, a +23% move from its current price of $0.6542. CELZ is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6141 | $0.6544 | $0.6973 | +0.03% |
| Aug 6 | $0.5983 | $0.6546 | $0.7161 | +0.06% |
| Aug 7 | $0.5865 | $0.6548 | $0.731 | +0.09% |
| Aug 8 | $0.5768 | $0.655 | $0.7437 | +0.12% |
| Aug 9 | $0.5684 | $0.6552 | $0.7552 | +0.15% |
| Aug 10 | $0.5609 | $0.6554 | $0.7658 | +0.18% |
| Aug 11 | $0.5541 | $0.6556 | $0.7756 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5541 | $0.6556 | $0.7756 | +0.21% |
| Week 2 | $0.5179 | $0.657 | $0.8333 | +0.42% |
| Week 3 | $0.492 | $0.6583 | $0.8809 | +0.63% |
| Week 4 | $0.4713 | $0.6597 | $0.9234 | +0.84% |
| Week 5 | $0.454 | $0.6611 | $0.9628 | +1.06% |
| Week 6 | $0.4389 | $0.6625 | $1.00 | +1.27% |
| Week 7 | $0.4255 | $0.6639 | $1.04 | +1.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
It develops AlloStem (CELZ-201-DDT), ImmCelz (CELZ-100), CELZ-201 CREATE-1 (phase 2 for type 1 diabetes), AlloStemSpine (CELZ 201 ADAPT) (phase 2 for chronic lower back pain), Alova, StemSpine, OvaStem, and CaverStem for erectile dysfunction treatment, as well as FemCelz and related platforms. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company focused on novel biological therapeutics in multiple fields, including immunotherapy, endocrinology, urology, neurology, and orthopedics, in the United States.
The stock is currently priced at $0.664 with a market cap of $4.31M and a rank of 5318.
The year-by-year forecast outlines a path with mixed outcomes: 2026 at an average of $0.664 and rising to $0.8141 in 2027, $0.8531 in 2028, and $0.8377 in 2029; a dip in 2030 to $0.6249, followed by gradual recovery through 2035 and beyond. The forecast also shows stronger upside later, with 2040 averaging $1.35 and 2050 averaging $2.11, and maximums reaching $2.97 in 2040 and $4.85 in 2050.
A major level 1.5% above — losing it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 240.9% above — a clean break opens room to run.
A major ceiling 320.7% above — clearing it would confirm fresh momentum.
Key CELZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CELZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.73 | Sell | $0.7279 | Sell |
| MA 10 | $0.7806 | Sell | $0.7799 | Sell |
| MA 20 | $0.8578 | Sell | $0.9341 | Sell |
| MA 50 | $1.56 | Sell | $1.35 | Sell |
| MA 100 | $1.84 | Sell | $1.69 | Sell |
| MA 200 | $2.16 | Sell | $2.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.68 | Buy |
| Stoch RSI (14) | 41.84 | Neutral |
| CCI (20) | -155.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -19.22 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.83 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 25.43 | Buy |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.69 | Sell |
| ADX (14) | 36.03 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 30. SMA50 is $1.56 and SMA200 is $2.16, framing resistance above the current price.
On the downside, there is support at $0.664, while resistance sits at $2.23. The 30-day price range spans $0.4368 to $1.01, and annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.6542 | $0.6542 | $1.00 | 0% | Neutral | |
| $0.5847 | $0.8023 | $1.19 | +23% | Bullish | |
| $0.5753 | $0.8397 | $1.33 | +28% | Bullish | |
| $0.5373 | $0.8264 | $1.37 | +26% | Bullish | |
| $0.3824 | $0.6168 | $1.07 | -6% | Neutral | |
| $0.4062 | $0.6849 | $1.23 | +5% | Neutral | |
| $0.4363 | $0.7674 | $1.42 | +17% | Neutral | |
| $0.4526 | $0.829 | $1.58 | +27% | Bullish | |
| $0.5592 | $1.07 | $2.08 | +63% | Bullish | |
| $0.5407 | $1.07 | $2.14 | +64% | Bullish | |
| $0.5989 | $1.33 | $2.92 | +103% | Bullish | |
| $0.9352 | $2.08 | $4.78 | +218% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.6542 | $0.6542 | $0.875 | +0.00% |
| September 2026 | $0.5788 | $0.7036 | $0.8922 | +7.54% |
| October 2026 | $0.5455 | $0.6724 | $0.8701 | -4.43% |
| November 2026 | $0.5688 | $0.7091 | $0.9326 | +5.47% |
| December 2026 | $0.5974 | $0.7525 | $1.00 | +6.13% |
Click any year to see its month-by-month CELZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Creative Medical Technology Holdings, Inc.'s 2026 outlook centres on $0.6542, within a $0.6542 to $1.00 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CELZ could reach as high as $1.19, with a base case around $0.8023 and support toward $0.5847 — roughly +23% from $0.6542. Momentum favours further upside here.
Expect CELZ to range from $0.5753 to $1.33 through 2028. The $0.8397 average target implies a +28% move from current prices. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CELZ price prediction for 2029 points to an average of $0.8264 (low $0.5373, high $1.37) — a potential gain of +26% on today's $0.6542. Momentum favours further upside here.
In 2030, CELZ is projected to trade between $0.3824 and $1.07, averaging $0.6168 — a potential decline of -6% from today's $0.6542. That is -25% versus the projected 2029 average. A consolidation phase looks the most probable path here.
Creative Medical Technology Holdings, Inc.'s 2031 outlook centres on $0.6849, within a $0.4062 to $1.23 range. That is up +11% on the projected 2030 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2032, CELZ could reach as high as $1.42, with a base case around $0.7674 and support toward $0.4363 — roughly +17% from $0.6542. A consolidation phase looks the most probable path here.
Expect CELZ to range from $0.4526 to $1.58 through 2033. The $0.829 average target implies a +27% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The CELZ price prediction for 2034 points to an average of $1.07 (low $0.5592, high $2.08) — a potential gain of +63% on today's $0.6542. Buyers look set to stay in control over this stretch.
In 2035, CELZ is projected to trade between $0.5407 and $2.14, averaging $1.07 — a potential gain of +64% from today's $0.6542. That is up +1% on the projected 2034 average. Momentum favours further upside here.
Creative Medical Technology Holdings, Inc.'s 2040 outlook centres on $1.33, within a $0.5989 to $2.92 range. That is up +24% on the projected 2035 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CELZ could reach as high as $4.78, with a base case around $2.08 and support toward $0.9352 — roughly +218% from $0.6542. Momentum favours further upside here.
Investing $1,000 in CELZ today (≈ 1,528.584531 CELZ) could be worth
$3,176.88
+$2,176.88 (+218%) by 2050 · US Dollar
Based on the average projected CELZ price of $2.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CELZwould be worth at today's price.
$1,000 invested in CELZ on Jul 31, 2025 (≈ 359.712234 CELZ) would be worth
$235.32
-$764.68 (-76.5%) today · 0.24× · US Dollar
Based on a CELZ entry price of $2.78 vs. today's $0.6542.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.8102 | $807.45 | -19.3% |
| 1 month ago | $1.27 | $515.12 | -48.5% |
| 3 months ago | $2.24 | $292.05 | -70.8% |
| 6 months ago | $2.08 | $314.52 | -68.5% |
| 1 year ago | $2.78 | $235.32 | -76.5% |
| All time (5.0y) ago | $144 | $4.54 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CELZ forecast.
Our base-case forecast reaches $1.30 around 2040.
Implied market cap at $1.30: $8.43M
The multi-year forecast shows a path of modest gains into 2029, followed by a dip in 2030 (min $0.3874, avg $0.6249, max $1.08, ROI -5.9%, sentiment NEUTRAL) before resuming a bullish trend in the 2030s and beyond.
From 2033 onward, the forecast turns more consistently bullish, with 2033 avg $0.8397 and max $1.60 (ROI 26.5%), 2034 avg $1.08 and max $2.11 (ROI 63.2%), and 2035 avg $1.09 and max $2.17 (ROI 63.7%). The long-term outlook strengthens further with 2040 avg $1.35 and max $2.97 (ROI 104%), and 2050 avg $2.11 and max $4.85 (ROI 217.3%). Overall, sentiment shifts to bullish in the later years, but a near-term dip is noted in 2030.
These figures illustrate meaningful upside potential in the distant horizon while highlighting near-term uncertainty.
Tap a question to reveal the answer.
In 2030, the forecast shows min $0.3874, avg $0.6249, max $1.08 with ROI -5.9% and sentiment NEUTRAL.
The forecast includes years with neutral to bullish outlook. 2027–2029 show bullish averages and positive ROIs (e.g., 2027 avg $0.8141 with 22.6% ROI; 2028 avg $0.8531 with 28.5% ROI; 2029 avg $0.8377 with 26.2% ROI). The long term also shows strong upside, particularly by 2040 and 2050 (ROI 104% and 217.3%). These are estimates, not guarantees.
The 2050 max forecast is $4.85, with 2050 avg $2.11 and ROI 217.3%. Therefore, reaching above $3 by 2050 is within the defined upper bound, while shorter horizons show maxs below $3 (e.g., 2040 max $2.97).
Current price is $0.664 and market cap is $4.31M.
2027 avg is $0.8141 (ROI 22.6%, bullish); 2028 avg is $0.8531 (ROI 28.5%, bullish); 2029 avg is $0.8377 (ROI 26.2%, bullish).
Creative Medical Technology Holdings, Inc. Community Discussion
0Share your Creative Medical Technology Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.